abstract: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, June 13, 2011

abstract: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial



Conclusions.


In selected patients with advanced stage EOC, upfront CRS and HIPEC provided promising results in terms of outcome. Morbidity was comparable to aggressive cytoreduction without HIPEC. Postoperative recovery delayed the initiation of adjuvant systemic chemotherapy but not sufficiently to impact negatively on survival. These data warrant further evaluation in a randomized clinical trial.

Highlights


► Maximal surgical effort and intraperitoneal chemotherapy have been proposed as upfront treatment in epithelial ovarian cancer.
► Primary cytoreduction and hyperthermic intraperitoneal chemotherapy was performed in advanced epithelial ovarian cancer patients.
► Promising survival rates and acceptable morbidity were reported.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.